Mediphage Bioceuticals

Phage-based Therapeutics

Undisclosed RD infectious diseases

Mediphage Bioceuticals is a Toronto-based biotech company, utilizing their next-generation non-viral gene therapy platform. They emerged as a spin-off from the University of Waterloo in 2016. Their proprietary ministring DNA (msDNA) technology and linear covalently closed non-viral DNA vector can bypass limitations of current widely used viral vector-based therapies, making it safer and more customizable, as well as allow for repeat dosing. There is an integrated method for prevention of unwanted integrations and mutations and no immunogenic pathogenic sequences. Mediphage is collaborating with other companies and research organizations to explore the potential of msDNA for various applications. Roderick Slavcev, founder and CSO, has over 25 years of research experience.